CoastWatcher
Moderator
At the present tine. flibanserin (Addyi, Valeant Pharmaceuticals) is the only approved therapy for hypoactive sexual desire disorder in women. However, it is only indicated for use in premenopausal women.
According to Dr. Sheryl Kingsberg, hypoactive sexual desire disorder is the most prevalent sexual dysfunction of women of all ages, but the highest rates are among postmenopausal women. Data presented by Kingsberg revealed that flibanserin was more effective than placebo in improving not only the desire domain on the Female Sexual Function Index, as previously reported by results from the Snow Drop Trial, but also improves all domains related to sexual function.
"Fibanserin May Be Effective Treatment For Hypoactive Sexual Desire in Post-Menopausal Women," Healio, Endocrine Today, 12 October 2017
https://www.healio.com/endocrinolog...exual-desire-disorder-in-postmenopausal-women
According to Dr. Sheryl Kingsberg, hypoactive sexual desire disorder is the most prevalent sexual dysfunction of women of all ages, but the highest rates are among postmenopausal women. Data presented by Kingsberg revealed that flibanserin was more effective than placebo in improving not only the desire domain on the Female Sexual Function Index, as previously reported by results from the Snow Drop Trial, but also improves all domains related to sexual function.
"Fibanserin May Be Effective Treatment For Hypoactive Sexual Desire in Post-Menopausal Women," Healio, Endocrine Today, 12 October 2017
https://www.healio.com/endocrinolog...exual-desire-disorder-in-postmenopausal-women
